temozolomide has been researched along with Necrosis in 28 studies
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
Excerpt | Relevance | Reference |
---|---|---|
"To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 7.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line." | 7.77 | Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011) |
"Temozolomide is the major drug in the treatment of malignant gliomas." | 7.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
"Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
" Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 7.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
"Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 6.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
"Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 5.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
"Osthole was the most effective." | 5.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
"Malignant melanomas are highly resistant to chemotherapy." | 5.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
"Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 5.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
"To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
"Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma." | 5.12 | Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. ( Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A, 2007) |
"The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor) and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells." | 4.02 | Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment. ( Bądziul, D; Hułas-Stasiak, M; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Pawelec, J; Pawlikowska-Pawlęga, B; Reichert, M; Rzeski, W; Sumorek-Wiadro, J; Wasiak, M; Wertel, I; Zając, A, 2021) |
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 3.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line." | 3.77 | Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011) |
"Temozolomide is the major drug in the treatment of malignant gliomas." | 3.76 | Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010) |
"Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
"Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
" Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 3.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
"Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 2.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
"Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
"Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
"Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 1.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
"Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
"Osthole was the most effective." | 1.56 | Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020) |
"Glioblastoma is the most common and aggressive glioma, characterized by brain invasion capability." | 1.48 | Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets. ( Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N, 2018) |
"Lycopene is a fat soluble red-orange carotenoid pigment present in tomato that reduces the risk for prostate cancer, a common malignancy among men." | 1.39 | Lycopene modulates growth and survival associated genes in prostate cancer. ( Bright, JJ; Kanakasabai, S; Rafi, MM; Reyes, MD, 2013) |
"Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
"Malignant melanomas are highly resistant to chemotherapy." | 1.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
"Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 1.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (25.00) | 29.6817 |
2010's | 15 (53.57) | 24.3611 |
2020's | 6 (21.43) | 2.80 |
Authors | Studies |
---|---|
Marinho, MAG | 1 |
da Silva Marques, M | 1 |
Lettnin, AP | 1 |
de Souza Votto, AP | 1 |
de Moraes Vaz Batista Filgueira, D | 1 |
Horn, AP | 1 |
Sumorek-Wiadro, J | 2 |
Zając, A | 2 |
Bądziul, D | 2 |
Langner, E | 3 |
Skalicka-Woźniak, K | 1 |
Maciejczyk, A | 2 |
Wertel, I | 2 |
Rzeski, W | 3 |
Jakubowicz-Gil, J | 3 |
Guo, L | 1 |
Li, X | 1 |
Chen, Y | 1 |
Liu, R | 1 |
Ren, C | 1 |
Du, S | 1 |
Park, YW | 1 |
Choi, D | 1 |
Park, JE | 1 |
Ahn, SS | 1 |
Kim, H | 1 |
Chang, JH | 1 |
Kim, SH | 1 |
Kim, HS | 1 |
Lee, SK | 1 |
Gao, F | 1 |
Zhao, W | 1 |
Li, M | 1 |
Ren, X | 1 |
Jiang, H | 1 |
Cui, Y | 1 |
Lin, S | 1 |
Pawlikowska-Pawlęga, B | 1 |
Pawelec, J | 1 |
Wasiak, M | 1 |
Hułas-Stasiak, M | 1 |
Reichert, M | 1 |
Yu, A | 1 |
Faiq, N | 1 |
Green, S | 1 |
Lai, A | 1 |
Green, R | 1 |
Hu, J | 1 |
Cloughesy, TF | 1 |
Mellinghoff, I | 1 |
Nghiemphu, PL | 1 |
Costa Nunes, F | 1 |
Silva, LB | 1 |
Winter, E | 1 |
Silva, AH | 1 |
de Melo, LJ | 1 |
Rode, M | 1 |
Martins, MAP | 1 |
Zanatta, N | 1 |
Feitosa, SC | 1 |
Bonacorso, HG | 1 |
Creczynski-Pasa, TB | 1 |
Winter, SF | 1 |
Loebel, F | 1 |
Loeffler, J | 1 |
Batchelor, TT | 1 |
Martinez-Lage, M | 1 |
Vajkoczy, P | 1 |
Dietrich, J | 1 |
Jablonska, PA | 1 |
Diez-Valle, R | 1 |
Pérez-Larraya, JG | 1 |
Moreno-Jiménez, M | 1 |
Idoate, MÁ | 1 |
Arbea, L | 1 |
Tejada, S | 1 |
Garcia de Eulate, MR | 1 |
Ramos, L | 1 |
Arbizu, J | 1 |
Domínguez, P | 1 |
Aristu, JJ | 1 |
Rafi, MM | 1 |
Kanakasabai, S | 1 |
Reyes, MD | 1 |
Bright, JJ | 1 |
Iuchi, T | 1 |
Hatano, K | 1 |
Kodama, T | 1 |
Sakaida, T | 1 |
Yokoi, S | 1 |
Kawasaki, K | 1 |
Hasegawa, Y | 1 |
Hara, R | 1 |
Karpel-Massler, G | 1 |
Westhoff, MA | 1 |
Kast, RE | 1 |
Dwucet, A | 1 |
Nonnenmacher, L | 1 |
Wirtz, CR | 1 |
Debatin, KM | 1 |
Halatsch, ME | 1 |
Rubner, Y | 1 |
Muth, C | 1 |
Strnad, A | 1 |
Derer, A | 1 |
Sieber, R | 1 |
Buslei, R | 1 |
Frey, B | 1 |
Fietkau, R | 1 |
Gaipl, US | 1 |
Peca, C | 1 |
Pacelli, R | 1 |
Elefante, A | 1 |
Del Basso De Caro, ML | 1 |
Vergara, P | 1 |
Mariniello, G | 1 |
Giamundo, A | 1 |
Maiuri, F | 1 |
Naumann, SC | 1 |
Roos, WP | 2 |
Jöst, E | 1 |
Belohlavek, C | 1 |
Lennerz, V | 1 |
Schmidt, CW | 1 |
Christmann, M | 1 |
Kaina, B | 2 |
Yaman, E | 1 |
Buyukberber, S | 1 |
Benekli, M | 1 |
Oner, Y | 1 |
Coskun, U | 1 |
Akmansu, M | 1 |
Ozturk, B | 1 |
Kaya, AO | 1 |
Uncu, D | 1 |
Yildiz, R | 1 |
Eich, M | 1 |
Dianov, GL | 1 |
Digweed, M | 1 |
Rusthoven, KE | 1 |
Olsen, C | 1 |
Franklin, W | 1 |
Kleinschmidt-DeMasters, BK | 1 |
Kavanagh, BD | 1 |
Gaspar, LE | 1 |
Lillehei, K | 1 |
Waziri, A | 1 |
Damek, DM | 1 |
Chen, C | 1 |
Matuschek, C | 1 |
Bölke, E | 1 |
Nawatny, J | 1 |
Hoffmann, TK | 1 |
Peiper, M | 1 |
Orth, K | 1 |
Gerber, PA | 1 |
Rusnak, E | 1 |
Lammering, G | 1 |
Budach, W | 1 |
Raghavan, D | 1 |
Boxerman, J | 1 |
Jeyapalan, S | 1 |
Rogg, J | 1 |
Lu, JQ | 1 |
Patel, S | 1 |
Wilson, BA | 1 |
Pugh, J | 1 |
Mehta, V | 1 |
Fuggetta, MP | 1 |
D'Atri, S | 1 |
Lanzilli, G | 1 |
Tricarico, M | 1 |
Cannavò, E | 1 |
Zambruno, G | 1 |
Falchetti, R | 1 |
Ravagnan, G | 1 |
Stamatakos, GS | 1 |
Antipas, VP | 1 |
Uzunoglu, NK | 1 |
Chamberlain, MC | 1 |
Glantz, MJ | 1 |
Chalmers, L | 1 |
Van Horn, A | 1 |
Sloan, AE | 1 |
Brandes, AA | 1 |
Franceschi, E | 1 |
Tosoni, A | 1 |
Blatt, V | 1 |
Pession, A | 1 |
Tallini, G | 1 |
Bertorelle, R | 1 |
Bartolini, S | 1 |
Calbucci, F | 1 |
Andreoli, A | 1 |
Frezza, G | 1 |
Leonardi, M | 1 |
Spagnolli, F | 1 |
Ermani, M | 1 |
Brandsma, D | 1 |
Stalpers, L | 1 |
Taal, W | 1 |
Sminia, P | 1 |
van den Bent, MJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577] | Phase 2 | 50 participants (Actual) | Interventional | 2012-12-07 | Active, not recruiting | ||
Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 reviews available for temozolomide and Necrosis
Article | Year |
---|---|
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
4 trials available for temozolomide and Necrosis
Article | Year |
---|---|
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
20 other studies available for temozolomide and Necrosis
Article | Year |
---|---|
Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell | 2021 |
Coumarins modulate the anti-glioma properties of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas | 2020 |
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob | 2021 |
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma; | 2021 |
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromones; Drug | 2021 |
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Ge | 2018 |
Lycopene modulates growth and survival associated genes in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carotenoids; Cell Cycle; Cell Line, Tumor; Cell | 2013 |
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ | 2009 |
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor | 2011 |
Radiation necrosis of a high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; | 2012 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2004 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |